What happened
Contineum's share price declined 9.9%, according to a report from Sina Finance.
The drop followed the failure of a mid-stage clinical trial for an antidepressant developed in collaboration with Johnson & Johnson.
Why it matters
A mid-stage trial failure is a significant setback for any drug program, and the market reaction suggests investors had placed meaningful expectations on this candidate.
Because the program involves a partnership with Johnson & Johnson, the outcome may affect how the collaboration is viewed going forward.
Key facts
Contineum shares fell 9.9%.
The decline was tied to the failure of a mid-stage antidepressant trial.
The antidepressant was developed in collaboration with Johnson & Johnson.
The report originated from Sina Finance.
What to watch next
Whether Contineum or Johnson & Johnson issue further statements about the trial or the partnership.
How the company's share price trades in subsequent sessions as the market digests the news.